Nadine M. Tung

1. Predicting pathologic complete response (pCR) from clinicopathologic variables and HER2DX genomic test in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): Secondary results from the EA1181/CompassHER2 pCR trial.
   2025/05/28 by Nadine Tung, Nadine M. Tung, Fengmin Zhao +24 · 1 citation
   Biochemistry, Genetics and Molecular Biology · Medicine · #Breast Cancer Treatment Studies #HER2/EGFR in Cancer Research #Lung Cancer Treatments and Mutations